요오드 결핍증 치료제 시장 : 제형별(정제, 기타), 유통 채널별(병원 약국, 드러그스토어와 소매 약국, 온라인 프로바이더) - 세계 기회 분석 및 산업 예측(2021-2031년)

Iodine is an essential trace element that is present in the thyroid hormones, thyroxine and triiodotyronine. These hormones play an important role in regulation of weight, energy levels, internal temperature, skin, hair, nail growth, metabolism and is an important part of the endocrine system. But in some cases thyroid gland is underactive i.e. it is unable to produce enough hormones due to which hypothyroidism occurs. The main cause of iodine deficiency disorder is hypothyroidism, which leads to development and metabolic problems. The adverse effects of hypothyroidism may lead to major problems such as abortion, still birth to mental and physical retardation and deafness.

The growth of global iodine deficiency drug market is driven by increase in iodine deficiency disorders, increase in awareness about iodine deficiency and also various drug launches by pharmaceutical key players. Moreover, the increase in prevalence of hypothyroidism cases in developing regions is a key factor which boosts the growth of market. Also, increase in prevalence of iodine deficiency cases in new born drives the growth of market. In addition, awareness programs across the globe by WHO, UNICEF for iodine deficiency will drive the market growth. For instance, according to WHO 2022, universal salt iodization program is introduced to combat iodine deficiency disorders across globe which fuels the growth of market.

However, side effects associated with iodine deficiency drugs and patent expiry of branded version are the restraints that decrease the growth of market. When thyroxine consumption is excess, various consequences can occur like thyroiditis, hyperthyroidism, and thyroid papillary cancer, brassy taste in the mouth, increased salivation, and gastrointestinal irritation which hinder the growth of market.

The global iodine deficiency drug market is segmented into dosage form, distribution channel and region wise. By dosage form, the market is categorized into tablets and others (softgel capsules, liquid formulations and injections). On the basis of distribution channel, the market is segregated into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major Key players that operate in the global iodine deficiency drug market are Abbott Laboratories, AbbVie Inc, Cipla Ltd, Fresenius SE & Co. KGaA (Fresenius Kabi), GlasxoSmithKline, Lupin, Macleods Pharmaceuticals, Merck KGaA, Pfizer, and Teva Pharmaceutical Industries Ltd, Inc.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the iodine deficiency drug market analysis from 2021 to 2031 to identify the prevailing iodine deficiency drug market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the iodine deficiency drug market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global iodine deficiency drug market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Distribution Channel

• Hospital Pharmacies
• Drug stores and Retail Pharmacies
• Online Providers

By Dosage Form

• Tablets
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
• Key Market Players
  • Cipla Ltd
  • Abbott Laboratories
  • Abbvie Inc
  • Fresenius SE and Co. KGaA
  • Glaxosmithkline plc
  • Lupin Ltd
  • Merck KGaA
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Macleods Pharmaceuticals Ltd

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

• 1.1.Report description
• 1.2.Key market segments
• 1.3.Key benefits to the stakeholders
• 1.4.Research Methodology
  • 1.4.1.Secondary research
  • 1.4.2.Primary research
  • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

• 2.1.Key findings of the study
• 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

• 3.1.Market definition and scope
• 3.2.Key findings
  • 3.2.1.Top investment pockets
• 3.3.Porter's five forces analysis
• 3.4.Top player positioning
• 3.5.Market dynamics
  • 3.5.1.Drivers
  • 3.5.2.Restraints
  • 3.5.3.Opportunities
• 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: IODINE DEFICIENCY DRUG MARKET, BY DOSAGE FORM

• 4.1 Overview
  • 4.1.1 Market size and forecast
• 4.2 Tablets
  • 4.2.1 Key market trends, growth factors and opportunities
  • 4.2.2 Market size and forecast, by region
  • 4.2.3 Market share analysis by country
• 4.3 Others
  • 4.3.1 Key market trends, growth factors and opportunities
  • 4.3.2 Market size and forecast, by region
  • 4.3.3 Market share analysis by country

CHAPTER 5: IODINE DEFICIENCY DRUG MARKET, BY DISTRIBUTION CHANNEL

• 5.1 Overview
  • 5.1.1 Market size and forecast
• 5.2 Hospital Pharmacies
  • 5.2.1 Key market trends, growth factors and opportunities
  • 5.2.2 Market size and forecast, by region
  • 5.2.3 Market share analysis by country
• 5.3 Drug stores and Retail Pharmacies
  • 5.3.1 Key market trends, growth factors and opportunities
  • 5.3.2 Market size and forecast, by region
  • 5.3.3 Market share analysis by country
• 5.4 Online Providers
  • 5.4.1 Key market trends, growth factors and opportunities
  • 5.4.2 Market size and forecast, by region
  • 5.4.3 Market share analysis by country

CHAPTER 6: IODINE DEFICIENCY DRUG MARKET, BY REGION

• 6.1 Overview
  • 6.1.1 Market size and forecast
• 6.2 North America
  • 6.2.1 Key trends and opportunities
  • 6.2.2 North America Market size and forecast, by Dosage Form
  • 6.2.3 North America Market size and forecast, by Distribution Channel
  • 6.2.4 North America Market size and forecast, by country
    • 6.2.4.1 U.S.
    • 6.2.4.1.1 Key market trends, growth factors and opportunities
    • 6.2.4.1.2 Market size and forecast, by Dosage Form
    • 6.2.4.1.3 Market size and forecast, by Distribution Channel
    • 6.2.4.2 Canada
    • 6.2.4.2.1 Key market trends, growth factors and opportunities
    • 6.2.4.2.2 Market size and forecast, by Dosage Form
    • 6.2.4.2.3 Market size and forecast, by Distribution Channel
    • 6.2.4.3 Mexico
    • 6.2.4.3.1 Key market trends, growth factors and opportunities
    • 6.2.4.3.2 Market size and forecast, by Dosage Form
    • 6.2.4.3.3 Market size and forecast, by Distribution Channel
• 6.3 Europe
  • 6.3.1 Key trends and opportunities
  • 6.3.2 Europe Market size and forecast, by Dosage Form
  • 6.3.3 Europe Market size and forecast, by Distribution Channel
  • 6.3.4 Europe Market size and forecast, by country
    • 6.3.4.1 Germany
    • 6.3.4.1.1 Key market trends, growth factors and opportunities
    • 6.3.4.1.2 Market size and forecast, by Dosage Form
    • 6.3.4.1.3 Market size and forecast, by Distribution Channel
    • 6.3.4.2 France
    • 6.3.4.2.1 Key market trends, growth factors and opportunities
    • 6.3.4.2.2 Market size and forecast, by Dosage Form
    • 6.3.4.2.3 Market size and forecast, by Distribution Channel
    • 6.3.4.3 UK
    • 6.3.4.3.1 Key market trends, growth factors and opportunities
    • 6.3.4.3.2 Market size and forecast, by Dosage Form
    • 6.3.4.3.3 Market size and forecast, by Distribution Channel
    • 6.3.4.4 Italy
    • 6.3.4.4.1 Key market trends, growth factors and opportunities
    • 6.3.4.4.2 Market size and forecast, by Dosage Form
    • 6.3.4.4.3 Market size and forecast, by Distribution Channel
    • 6.3.4.5 Spain
    • 6.3.4.5.1 Key market trends, growth factors and opportunities
    • 6.3.4.5.2 Market size and forecast, by Dosage Form
    • 6.3.4.5.3 Market size and forecast, by Distribution Channel
    • 6.3.4.6 Rest of Europe
    • 6.3.4.6.1 Key market trends, growth factors and opportunities
    • 6.3.4.6.2 Market size and forecast, by Dosage Form
    • 6.3.4.6.3 Market size and forecast, by Distribution Channel
• 6.4 Asia-Pacific
  • 6.4.1 Key trends and opportunities
  • 6.4.2 Asia-Pacific Market size and forecast, by Dosage Form
  • 6.4.3 Asia-Pacific Market size and forecast, by Distribution Channel
  • 6.4.4 Asia-Pacific Market size and forecast, by country
    • 6.4.4.1 Japan
    • 6.4.4.1.1 Key market trends, growth factors and opportunities
    • 6.4.4.1.2 Market size and forecast, by Dosage Form
    • 6.4.4.1.3 Market size and forecast, by Distribution Channel
    • 6.4.4.2 China
    • 6.4.4.2.1 Key market trends, growth factors and opportunities
    • 6.4.4.2.2 Market size and forecast, by Dosage Form
    • 6.4.4.2.3 Market size and forecast, by Distribution Channel
    • 6.4.4.3 India
    • 6.4.4.3.1 Key market trends, growth factors and opportunities
    • 6.4.4.3.2 Market size and forecast, by Dosage Form
    • 6.4.4.3.3 Market size and forecast, by Distribution Channel
    • 6.4.4.4 Australia
    • 6.4.4.4.1 Key market trends, growth factors and opportunities
    • 6.4.4.4.2 Market size and forecast, by Dosage Form
    • 6.4.4.4.3 Market size and forecast, by Distribution Channel
    • 6.4.4.5 South Korea
    • 6.4.4.5.1 Key market trends, growth factors and opportunities
    • 6.4.4.5.2 Market size and forecast, by Dosage Form
    • 6.4.4.5.3 Market size and forecast, by Distribution Channel
    • 6.4.4.6 Rest of Asia-Pacific
    • 6.4.4.6.1 Key market trends, growth factors and opportunities
    • 6.4.4.6.2 Market size and forecast, by Dosage Form
    • 6.4.4.6.3 Market size and forecast, by Distribution Channel
• 6.5 LAMEA
  • 6.5.1 Key trends and opportunities
  • 6.5.2 LAMEA Market size and forecast, by Dosage Form
  • 6.5.3 LAMEA Market size and forecast, by Distribution Channel
  • 6.5.4 LAMEA Market size and forecast, by country
    • 6.5.4.1 Brazil
    • 6.5.4.1.1 Key market trends, growth factors and opportunities
    • 6.5.4.1.2 Market size and forecast, by Dosage Form
    • 6.5.4.1.3 Market size and forecast, by Distribution Channel
    • 6.5.4.2 Saudi Arabia
    • 6.5.4.2.1 Key market trends, growth factors and opportunities
    • 6.5.4.2.2 Market size and forecast, by Dosage Form
    • 6.5.4.2.3 Market size and forecast, by Distribution Channel
    • 6.5.4.3 South Africa
    • 6.5.4.3.1 Key market trends, growth factors and opportunities
    • 6.5.4.3.2 Market size and forecast, by Dosage Form
    • 6.5.4.3.3 Market size and forecast, by Distribution Channel
    • 6.5.4.4 Rest of LAMEA
    • 6.5.4.4.1 Key market trends, growth factors and opportunities
    • 6.5.4.4.2 Market size and forecast, by Dosage Form
    • 6.5.4.4.3 Market size and forecast, by Distribution Channel

CHAPTER 7: COMPANY LANDSCAPE

• 7.1. Introduction
• 7.2. Top winning strategies
• 7.3. Product Mapping of Top 10 Player
• 7.4. Competitive Dashboard
• 7.5. Competitive Heatmap
• 7.6. Key developments

CHAPTER 8: COMPANY PROFILES

• 8.1 Abbott Laboratories
  • 8.1.1 Company overview
  • 8.1.2 Company snapshot
  • 8.1.3 Operating business segments
  • 8.1.4 Product portfolio
  • 8.1.5 Business performance
  • 8.1.6 Key strategic moves and developments
• 8.2 Abbvie Inc
  • 8.2.1 Company overview
  • 8.2.2 Company snapshot
  • 8.2.3 Operating business segments
  • 8.2.4 Product portfolio
  • 8.2.5 Business performance
  • 8.2.6 Key strategic moves and developments
• 8.3 Cipla Ltd
  • 8.3.1 Company overview
  • 8.3.2 Company snapshot
  • 8.3.3 Operating business segments
  • 8.3.4 Product portfolio
  • 8.3.5 Business performance
  • 8.3.6 Key strategic moves and developments
• 8.4 Fresenius SE and Co. KGaA
  • 8.4.1 Company overview
  • 8.4.2 Company snapshot
  • 8.4.3 Operating business segments
  • 8.4.4 Product portfolio
  • 8.4.5 Business performance
  • 8.4.6 Key strategic moves and developments
• 8.5 Glaxosmithkline plc
  • 8.5.1 Company overview
  • 8.5.2 Company snapshot
  • 8.5.3 Operating business segments
  • 8.5.4 Product portfolio
  • 8.5.5 Business performance
  • 8.5.6 Key strategic moves and developments
• 8.6 Lupin Ltd
  • 8.6.1 Company overview
  • 8.6.2 Company snapshot
  • 8.6.3 Operating business segments
  • 8.6.4 Product portfolio
  • 8.6.5 Business performance
  • 8.6.6 Key strategic moves and developments
• 8.7 Macleods Pharmaceuticals Ltd
  • 8.7.1 Company overview
  • 8.7.2 Company snapshot
  • 8.7.3 Operating business segments
  • 8.7.4 Product portfolio
  • 8.7.5 Business performance
  • 8.7.6 Key strategic moves and developments
• 8.8 Merck KGaA
  • 8.8.1 Company overview
  • 8.8.2 Company snapshot
  • 8.8.3 Operating business segments
  • 8.8.4 Product portfolio
  • 8.8.5 Business performance
  • 8.8.6 Key strategic moves and developments
• 8.9 Pfizer Inc.
  • 8.9.1 Company overview
  • 8.9.2 Company snapshot
  • 8.9.3 Operating business segments
  • 8.9.4 Product portfolio
  • 8.9.5 Business performance
  • 8.9.6 Key strategic moves and developments
• 8.10 Teva Pharmaceutical Industries Ltd.
  • 8.10.1 Company overview
  • 8.10.2 Company snapshot
  • 8.10.3 Operating business segments
  • 8.10.4 Product portfolio
  • 8.10.5 Business performance
  • 8.10.6 Key strategic moves and developments